MUMBAI, India, May 29 -- Intellectual Property India has published a patent application (202641062351 A) filed by Adichunchanagiri University; and Adichunchanagiri Institute Of Medical Sciences, Mandya, Karnataka, on May 16, for 'phosphatidylinositol 3- kinase (pi3k) and phosphatase and tensin homolog (pten) expression in breast cancer and its correlation with clinicopathological prognostic markers.'
Inventor(s) include Dr. Prescila Christopher; and Dr. Amita K.
The application for the patent was published on May 29, under issue no. 22/2026.
According to the abstract released by the Intellectual Property India: "The present invention proposes a novel dual-biomarker immunohistochemical assessment system and method, termed the PI3K-PTEN Integrated Pathway Profiling Platform, designed to evaluate the expression patterns of PI3K and PTEN in invasive breast carcinoma tissues for improved molecular characterization, identification of actionable subgroups, and support for personalized therapeutic decision-making. By combining standardized IHC protocols with quantitative correlation analysis, the system effectively detects high PI3K prevalence alongside PTEN alterations and their inverse relationship, providing clinicians with a practical tool to stratify patients who may benefit from targeted PI3K pathway inhibitors while addressing the limitations of traditional clinicopathological parameters alone."
Disclaimer: Curated by HT Syndication.
